Janux Therapeutics Inc JANX Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Nov 13, 2023 (filed on Nov 15, 2023)

Insider Name:

Reardon Tighe

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

849,854

Price:

$5.87
Nov 13, 2023 (filed on Nov 15, 2023)

Insider Name:

Lichter Jay

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

849,854

Price:

$5.87
Nov 13, 2023 (filed on Nov 13, 2023)

Insider Name:

Avalon Ventures XI, L.P.

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

849,854

Price:

$5.87
Jul 19, 2023 (filed on Jul 21, 2023)

Insider Name:

Ra Capital Management, L.P.

Ownership Type:

Indirect Ownership

Securities:

Pre-Funded Warrants (Right to Buy)

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

503,226

Price:

$12.46
Jul 19, 2023 (filed on Jul 21, 2023)

Insider Name:

Ra Capital Management, L.P.

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

495,008

Price:

$12.46
Jun 14, 2023 (filed on Jun 16, 2023)

Insider Name:

Lichter Jay

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,500

Price:

--
Jun 14, 2023 (filed on Jun 16, 2023)

Insider Name:

McNulty Alana B.

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,500

Price:

--
Jun 14, 2023 (filed on Jun 16, 2023)

Insider Name:

Simson Jake

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,500

Price:

--
Jun 14, 2023 (filed on Jun 16, 2023)

Insider Name:

Kung Winston

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,500

Price:

--
Jun 14, 2023 (filed on Jun 16, 2023)

Insider Name:

Gujrathi Sheila

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,500

Price:

--

Filings by filing date

Nov 13, 2023 (filed on Nov 15, 2023)

Insider Name:

Reardon Tighe

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

849,854

Price:

$5.87
Nov 13, 2023 (filed on Nov 15, 2023)

Insider Name:

Lichter Jay

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

849,854

Price:

$5.87
Nov 13, 2023 (filed on Nov 13, 2023)

Insider Name:

Avalon Ventures XI, L.P.

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

849,854

Price:

$5.87
Jul 19, 2023 (filed on Jul 21, 2023)

Insider Name:

Ra Capital Management, L.P.

Ownership Type:

Indirect Ownership

Securities:

Pre-Funded Warrants (Right to Buy)

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

503,226

Price:

$12.46
Jul 19, 2023 (filed on Jul 21, 2023)

Insider Name:

Ra Capital Management, L.P.

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

495,008

Price:

$12.46
Jun 14, 2023 (filed on Jun 16, 2023)

Insider Name:

Lichter Jay

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,500

Price:

--
Jun 14, 2023 (filed on Jun 16, 2023)

Insider Name:

McNulty Alana B.

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,500

Price:

--
Jun 14, 2023 (filed on Jun 16, 2023)

Insider Name:

Simson Jake

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,500

Price:

--
Jun 14, 2023 (filed on Jun 16, 2023)

Insider Name:

Kung Winston

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,500

Price:

--
Jun 14, 2023 (filed on Jun 16, 2023)

Insider Name:

Gujrathi Sheila

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,500

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	10955 Vista Sorrento Parkway, Suite 200 SAN DIEGO CA 92130
Tel:	N/A
Website:	https://www.januxrx.com
IR:	See website

Key People

Jay B. Lichter Chairman of the Board	David Campbell President, Chief Executive Officer, Founder, Director	Tighe Reardon Acting Chief Financial Officer
Charles Winter Chief Technology Officer	Andy Meyer Chief Business Officer	Byron Robinson Interim Chief Medical Officer

Business Overview

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is engaged in developing a pipeline of immunotherapies by applying its technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to treat patients suffering from cancer. Its initial focus is on developing a class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. It is developing a pipeline with programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Its pipeline includes PSMA-TRACTr, EGFR-TRACTr, and TROP2-TRACTr. PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. Its EGFR-TRACTr is designed to target EGFR. TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target. Its TRACIr program targets PD-L1xCD28.

Financial Overview

For the nine months ended 30 September 2023, Janux Therapeutics Inc revenues decreased 3% to $5.6M. Net loss decreased 1% to $46.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Interest income increase from $1.8M to $10.3M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.13 to -$1.09.

Employees:	60 as of Dec 31, 2022

Reporting Currency:	U.S. Dollars
Enterprise value:	$85.19M as of Sep 30, 2023
Annual revenue (TTM):	$8.47M as of Sep 30, 2023
EBITDA (TTM):	-$73.28M as of Sep 30, 2023
Net annual income (TTM):	-$62.60M as of Sep 30, 2023
Free cash flow (TTM):	-$55.98M as of Sep 30, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	46,168,430 as of Nov 3, 2023
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization